Your shopping cart is currently empty

TAT-CBD3A6K acetate is a modified TAT-CBD3 peptide. It decreases T-type and R-type voltage-dependent calcium currents in dorsal root ganglion (DRG) neurons. By inhibiting CRMP-2 mediated enhancement of T-type and R-type calcium channel functions, TAT-CBD3A6K acetate demonstrates anti-nociception in a model of AIDS-induced peripheral neuropathy.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | TAT-CBD3A6K acetate is a modified TAT-CBD3 peptide. It decreases T-type and R-type voltage-dependent calcium currents in dorsal root ganglion (DRG) neurons. By inhibiting CRMP-2 mediated enhancement of T-type and R-type calcium channel functions, TAT-CBD3A6K acetate demonstrates anti-nociception in a model of AIDS-induced peripheral neuropathy. |
| Sequence | Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Ala-Arg-Ser-Arg-Leu-Lys-Glu-Leu-Arg-Gly-Val-Pro-Arg-Gly-Leu |
| Sequence Short | YGRKKRRQRRRARSRLKELRGVPRGL |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.